Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect with Christy J. Wilson on LinkedIn
Follow Christy J. Wilson on Twitter
About the author:
Christy brings more than 20 years of global life science and healthcare industry experience to her role as Senior Director, Segment Marketing for the biopharmaceutical industry segment at Elsevier. In this capacity she is focused on understanding biopharmaceutical R&D challenges and the implications for Elsevier in terms of market led growth opportunities that will improve productivity and success for industry executives and their teams. She also plays a key role in increasing Elsevier’s share-of-voice and market share through strategic go-to-market planning and execution.
Prior to joining Elsevier, Christy held senior marketing and business development roles in Wolters Kluwer’s Pharma Solutions Business Unit where she was responsible for product management and marketing of the Adis portfolio of drug focused journals and newsletters, pipeline and clinical trials intelligence tools, and pharmacovigilance solutions. During her Wolters Kluwer tenure, Christy also worked in the group’s Healthcare Analytics business, a business that provided powerful data, applications, analytics, and consulting to help companies gain deep insight into the pharmaceutical market.
Christy resides in the greater New York City area and holds an MBA in International Business from DePaul University (Chicago) and a BS in Marketing, from Miami University (Ohio).
Posts by Christy J. Wilson
Posted on November 22nd, 2018 in Pharma R&D
Since our founding back in 2006, LegoChem Biosciences (LCB) has focused on the research and development of anti-biotic, anti-coagulant, anti-fibrosis and Antibody-Drug Conjugate (ADC) therapeutics based on our proprietary platform technology, LegoChemistry™ & Conjuall™. LCB is comprised of researchers who have varied backgrounds and R&D experiences, including the development of Factive, the first US FDA-approved drug developed in Korea. (more…)
Posted on November 19th, 2018 in Pharma R&D
The hard work of drug development often goes down well-worn paths that can be tedious, time-consuming and frustrating, but – with time and dedication – can yield exciting results. Sometimes, however, scientists who think outside the box find themselves taking unconventional routes in their efforts to create innovative new therapies. (more…)
Posted on November 15th, 2018 in Pharma R&D
October 2018 started with Cern professor Alessandro Stumia’s disparaging speech about women in which he proclaimed, to a predominately female audience of physicists, that ‘physics was invented and built by men, it’s not by invitation’. (more…)
Posted on November 14th, 2018 in Pharma R&D
90 years ago, an accidental discovery was made which altered medicine forever. While sorting through petri dishes in his laboratory, Alexander Fleming came across a substance we now know as penicillin, which prevented mold growing on the dish. (more…)